Alphatec Holdings Inc (ATEC)

Currency in USD
9.57
-0.78(-7.54%)
Closed·
9.66+0.09(+0.94%)
·
ATEC is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
9.2610.10
52 wk Range
6.8223.29
Key Statistics
Prev. Close
9.57
Open
9.87
Day's Range
9.26-10.1
52 wk Range
6.82-23.29
Volume
5.22M
Average Volume (3m)
3.37M
1-Year Change
-37.0395%
Book Value / Share
-0.08
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ATEC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
15.92
Upside
+66.39%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

Alphatec Holdings Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 15.92
(+66.39% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy16.00+67.19%15.00MaintainAug 05, 2026
TD Cowen
Buy13.00+35.84%11.00MaintainAug 05, 2026
BMO Capital
Buy12.00+25.39%11.00MaintainAug 05, 2026
UBS
Buy15.00+56.74%-New CoverageJul 28, 2026
Stephens
Buy15.00+56.74%-New CoverageJul 23, 2026

Alphatec Holdings Inc Earnings Call Summary for Q2/2026

  • Q2 revenue rose 15% YoY to $214M, beating $211.24M forecast; adjusted EBITDA jumped 53% to $36M with margin expanding to 17%.
  • ATEC raised full-year 2026 adjusted EBITDA guidance to $140M from $134M while maintaining revenue guidance at $882M, representing 15% growth.
  • Net new surgeon growth reached 24% and case volume increased 20%, though revenue per case fell 2.7% YoY due to mix pressures and weak biologics.
  • Gross margin improved 260 basis points to 72.5%; free cash flow turned slightly positive at $1M after $33M in inventory and instrument investments.
  • Management expects Q3 free cash flow of $4M-$6M and second-half surgical revenue growth to accelerate to 18% with case volume growth in high teens.
Last Updated: 08/05/2026, 05:58 AM
Read Full Transcript

Earnings

Latest Release
Aug 04, 2026
EPS / Forecast
0.07 / 0.07
Revenue / Forecast
214M / 211.24M
EPS Revisions
Last 90 days

ATEC Income Statement

Compare ATEC to Peers and Sector

Metrics to compare
ATEC
Peers
Sector
Relationship
P/E Ratio
−13.4x−8.7x−0.4x
PEG Ratio
−0.36−0.390.00
Price/Book
−122.5x3.7x2.6x
Price / LTM Sales
1.8x2.4x3.0x
Upside (Analyst Target)
56.7%38.6%51.8%
Fair Value Upside
Unlock11.8%7.2%Unlock

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
47.51M30.89%454.66M
Other Institutional Investors
86.96M56.54%832.21M
Public Companies & Retail Investors
19.32M12.56%184.90M
Total
153.79M100.00%1.47B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Squadron Capital, LLC6.76%10,395,04599,481
BlackRock, Inc.6.56%10,088,18296,544

People Also Watch

109.87
EPAM
-1.95%
133.26
PODD
-20.12%
108.27
SPCX
-13.61%
9.2600
ADMA
+3.93%
68.610
AXTI
+5.12%

FAQ

What Is the Alphatecs (ATEC) Stock Price Today?

The Alphatecs stock price today is 9.57 USD.

What Stock Exchange Does Alphatecs Trade On?

Alphatecs is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Alphatecs?

The stock symbol for Alphatecs is "ATEC."

What Is the Alphatecs Market Cap?

As of today, Alphatecs market cap is 1.48B USD.

What Is Alphatecs's Earnings Per Share (TTM)?

The Alphatecs EPS (TTM) is -0.83.

When Is the Next Alphatecs Earnings Date?

Alphatecs will release its next earnings report on Oct 29, 2026.

From a Technical Analysis Perspective, Is ATEC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Alphatecs Stock Split?

Alphatecs has split 1 times.

How Many Employees Does Alphatecs Have?

Alphatecs has 913 employees.

What is the current trading status of Alphatecs (ATEC)?

As of Aug 06, 2026, Alphatecs (ATEC) is trading at a price of 9.57 USD, with a previous close of 9.57 USD. The stock has fluctuated within a day range of 9.26 USD to 10.10 USD, while its 52-week range spans from 6.82 USD to 23.29 USD.

What Is Alphatecs (ATEC) Price Target According to Analysts?

The average 12-month price target for Alphatecs is 15.92 USD, with a high estimate of 24 USD and a low estimate of 12 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +66.39% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.